Table 2.

Incidence rates of both outcomes with the follow-up duration restricted to the longest observed follow-up duration of the 2015–2021 group (6.7 years), stratified by the year of androgen deprivation therapy initiation.

Year of androgen deprivation therapy initiation	Major adverse cardiovascular events		All-cause mortality
	Incidence ratea	Incidence rate ratio	Incidence ratea	Incidence rate ratio
1993–2000	4.4 [3.7, 5.1]	1 (reference)	20.3 [19.0, 21.8]	1 (reference)
2001–2007	4.7 [4.3, 5.1]	1.07 [0.89, 1.28], P = 0.479	14.5 [13.9, 15.2]	0.71 [0.66, 0.78], P < 0.001
2008–2014	5.4 [5.0, 5.7]	1.23 [1.04, 1.47], P = 0.019	13.9 [13.4, 14.5]	0.69 [0.63, 0.74], P < 0.001
2015–2021	5.7 [5.3, 6.2]	1.32 [1.10, 1.58], P = 0.003	15.9 [15.2, 16.6]	0.78 [0.72, 0.85], P < 0.001

^aPer 100 person-year.

Incidence rate ratios displayed were referenced against the 1993–2000 group.